Jennifer Halchak; VP, IR; Organon & Co. Kevin Ali; Chief Executive Officer, Director; Organon & Co. Matthew Walsh; Chief Financial Officer, Senior Vice President; Or ...

For recently acquired Tofidence, that product is manufactured in China, but we have inventory coverage offering us protection through 2025. The denosumab asset from Shanghai Henlius is not planned ...

This news release contains certain forward-looking statements relating to BAT8006, BAT8008, BAT8010, BAT1006, BAT1308 or the product pipelines in general of Bio-Thera Solutions. Readers are ...

The intravenous biosimilar of IL-6 inhibitor Actemra (tocilizumab) – called Tofidence (formerly BIIB800) – has been cleared for three of the indications for which Roche’s drug is used ...

In another development, Organon has acquired the U.S. rights to TOFIDENCE™, a biosimilar to ACTEMRA®, from Biogen, further expanding its arthritis treatment portfolio. Furthermore, Biogen plans to ...

The market is also upbeat about Organon’s recently acquired regulatory and commercial rights in the United States for TOFIDENCE from Biogen Inc. TOFIDENCE is the first approved tocilizumab ...

At the top of April, Organon announced the acquisition of Tofidence (tocilizumab-bavi), a biosimilar approved by the FDA in October 2023 for the treatment of rheumatoid arthritis, giant cell arteritis ...